Literature DB >> 29230138

Introduction to Biosimilar Use in Patients With Inflammatory Bowel Disease.

Gary R Lichtenstein1.   

Abstract

Entities:  

Year:  2017        PMID： 29230138      PMCID： PMC5718178     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

Review 1.  Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.

Authors:  Y Komaki; A Yamada; F Komaki; D Micic; A Ido; A Sakuraba
Journal:  Aliment Pharmacol Ther       Date:  2017-02-26       Impact factor: 8.171

2.  ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.

Authors:  Silvio Danese; Gionata Fiorino; Tim Raine; Marc Ferrante; Karen Kemp; Jaroslaw Kierkus; Peter L Lakatos; Gerassimos Mantzaris; Janneke van der Woude; Julian Panes; Laurent Peyrin-Biroulet
Journal:  J Crohns Colitis       Date:  2016-12-07       Impact factor: 9.071

Review 3.  Biosimilars in IBD: from theory to practice.

Authors:  Silvio Danese; Stefanos Bonovas; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

4.  A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

Authors:  Dae Hyun Yoo; Pawel Hrycaj; Pedro Miranda; Edgar Ramiterre; Mariusz Piotrowski; Sergii Shevchuk; Volodymyr Kovalenko; Nenad Prodanovic; Mauricio Abello-Banfi; Sergio Gutierrez-Ureña; Luis Morales-Olazabal; Michael Tee; Renato Jimenez; Omid Zamani; Sang Joon Lee; HoUng Kim; Won Park; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2013-05-16       Impact factor: 19.103

5.  A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.

Authors:  Won Park; Pawel Hrycaj; Slawomir Jeka; Volodymyr Kovalenko; Grygorii Lysenko; Pedro Miranda; Helena Mikazane; Sergio Gutierrez-Ureña; MieJin Lim; Yeon-Ah Lee; Sang Joon Lee; HoUng Kim; Dae Hyun Yoo; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2013-05-16       Impact factor: 19.103
  5 in total
  1 in total

1.  Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia.

Authors:  Yazed AlRuthia; Othman Alharbi; Abdulrahman M Aljebreen; Nahla A Azzam; Majid A Almadi; Ohud H Bahari; Khalid A Almalki; Abdulaziz T Atham; Ahmed S Alanazi; Maria Saeed; Baraa HajkhderMullaissa; Mohammad Alsenaidy; Bander Balkhi
Journal:  Cost Eff Resour Alloc       Date:  2019-12-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.